Federated Hermes, Inc. Relmada Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.3 - $4.36 $19,745 - $37,430	-8,585 Reduced 8.94%	87,425 $283,000
Q1 2024 May 14, 2024	SELL	$3.1 - $6.8 $11,869 - $26,037	-3,829 Reduced 3.84%	96,010 $446,000
Q4 2023 Jan 31, 2024	SELL	$2.45 - $4.22 $35,189 - $60,611	-14,363 Reduced 12.58%	99,839 $413,000
Q3 2023 Nov 13, 2023	BUY	$2.48 - $3.79 $193 - $295	78 Added 0.07%	114,202 $342,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $253,355 - $403,998	114,124 New	114,124 $280,000

8.29M

364K

46.5K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $8.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.